Align Technology is a manufacturer of 3D digital scanners and the Invisalign clear aligners used in orthodontics. It is headquartered in San Jose, California.
| Revenue (TTM) | $4.14B |
| Gross Profit (TTM) | $2.93B |
| EBITDA | $925.66M |
| Operating Margin | 18.20% |
| Return on Equity | 10.20% |
| Return on Assets | 7.56% |
| Revenue/Share (TTM) | $57.70 |
| Book Value | $59.41 |
| Price-to-Book | 2.49 |
| Price-to-Sales (TTM) | 2.52 |
| EV/Revenue | 2.306 |
| EV/EBITDA | 10.53 |
| Quarterly Earnings Growth (YoY) | -12.10% |
| Quarterly Revenue Growth (YoY) | 4.30% |
| Shares Outstanding | $71.04M |
| Float | $66.84M |
| % Insiders | 6.13% |
| % Institutions | 105.16% |
Volatility is currently expanding
Align Technology NASDAQ: ALGN sees continued growth potential for Invisalign clear aligners in the United States and internationally despite a challenging consumer environment, Chief Financial Officer John Morici said during a Baird investor conference.
Align Technology, Inc. (ALGN) Presents at 2026 Global Healthcare Conference Transcript
Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following financial conference. The presentation will be webcast live via the Investor Relations section of Align's website at ht.
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock?
Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.
ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.
SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a.
Align Technology delivers record revenue, volume, and operating margins, yet trades near five-year valuation lows despite structural business improvements. Competitive pressures have eased post-SmileDirectClub exit, with ALGN retaining dominant market share and shifting growth toward international and DSO channels. Operating margins are expanding, management continues to raise guidance, and a robust buyback program is underway, supported by strong free cash flow.
Align Technology delivered record Q2 revenue and clear aligner volumes, with robust international growth offsetting North American stagnation. ALGN's strategy centers on expanding its digital dentistry platform, leveraging financing, lower-cost products, and ecosystem growth to drive recurring revenue. Valuation at $173 per share (15–16x forward earnings) is attractive for a market leader with high margins, net cash, and ongoing share buybacks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALGN and any ticker you trade — then tracks every position and per-strategy win rate.
